Back
Related Posts
XENOTHERA strengthens its position in oncology and announces several clinical advances and scientific publications
October, 2025. Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco-humanized antibody (GH-pAb) programs. The company today announces new clinical milestones and major publications
Read MoreXENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody
June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone
Read MoreXENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France
June, 2024. During its participation in ASCO, XENOTHERA….
Read More